Rohto Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	343,725	308,625	270,840	238,664	199,646
Revenue Growth (YoY)	11.37%	13.95%	13.48%	19.54%	10.13%
Cost of Revenue	151,030	133,686	113,554	101,243	83,157
Gross Profit	192,695	174,939	157,286	137,421	116,489
Selling, General & Admin	128,129	115,521	101,377	89,859	76,435
Research & Development	13,727	14,912	13,390	11,065	8,740
Amortization of Goodwill & Intangibles	2,048	1,523	436	383	457
Operating Expenses	151,986	136,474	117,119	103,883	88,297
Operating Income	40,709	38,465	40,167	33,538	28,192
Interest Expense	-1,284	-949	-196	-247	-248
Interest & Investment Income	5,542	1,922	2,009	2,285	751
Earnings From Equity Investments	495	166	-289	56	143
Currency Exchange Gain (Loss)	1,338	516	447	-	-
Other Non Operating Income (Expenses)	1,168	311	294	-64	245
EBT Excluding Unusual Items	47,968	40,431	42,432	35,568	29,083
Gain (Loss) on Sale of Investments	-892	1,896	-798	-160	-368
Gain (Loss) on Sale of Assets	-15	-	-	-	-
Asset Writedown	-241	-175	-348	-1,338	-892
Other Unusual Items	-	179	230	219	129
Pretax Income	46,820	42,331	41,516	34,289	27,952
Income Tax Expense	12,404	11,379	10,123	7,860	6,803
Earnings From Continuing Operations	34,416	30,952	31,393	26,429	21,149
Minority Interest in Earnings	-169	54	-457	-52	-131
Net Income	34,247	31,006	30,936	26,377	21,018
Net Income to Common	34,247	31,006	30,936	26,377	21,018
Net Income Growth	10.45%	0.23%	17.28%	25.50%	25.53%
Shares Outstanding (Basic)	226	228	228	228	228
Shares Outstanding (Diluted)	235	229	229	229	229
Shares Change (YoY)	2.87%	0.04%	-	-0.00%	-
EPS (Basic)	151.56	136.11	135.60	115.62	92.13
EPS (Diluted)	145.29	135.44	135.21	115.29	91.86
EPS Growth	7.27%	0.17%	17.28%	25.50%	25.53%
Free Cash Flow	36,294	27,837	26,266	22,451	16,983
Free Cash Flow Per Share	154.14	121.61	114.80	98.13	74.23
Dividend Per Share	46.000	36.000	27.000	22.000	18.000
Dividend Growth	27.78%	33.33%	22.73%	22.22%	28.57%
Gross Margin	56.06%	56.68%	58.07%	57.58%	58.35%
Operating Margin	11.84%	12.46%	14.83%	14.05%	14.12%
Profit Margin	9.96%	10.05%	11.42%	11.05%	10.53%
Free Cash Flow Margin	10.56%	9.02%	9.70%	9.41%	8.51%
EBITDA	58,086	51,608	48,854	41,339	35,865
EBITDA Margin	16.90%	16.72%	18.04%	17.32%	17.96%
D&A For EBITDA	17,377	13,143	8,687	7,801	7,673
EBIT	40,709	38,465	40,167	33,538	28,192
EBIT Margin	11.84%	12.46%	14.83%	14.05%	14.12%
Effective Tax Rate	26.49%	26.88%	24.38%	22.92%	24.34%
Advertising Expenses	62,602	57,506	54,219	46,467	38,114

Source: S&P Global Market Intelligence. Standard template. Financial Sources.